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Background: Stent fracture (SF) after DES implantation has recently become an
important concern because of its potential association with in-stent restenosis and stent
thrombosis. However, the incidence and clinical relevance to SF after second gener-
ation DES (zotarolimus-eluting stent: ZES, everolimus-eluting stent: EES, and bio-
limus-eluting stent: BES) remain unclear, so the aim of study is to reveal clinical
impact of SF after second generation DES deployment.
Methods: A total of 1734 patients with 2185 lesions undergoing second generation
DES implantation and follow-up angiography within 12 months were performed from
April 2009 to September 2012 in a single center. We divided into SF group and non-
SF group and assessed the rates of SF and major adverse cardiac events (MACE),
deﬁned as death, myocardial infarction, stent thrombosis, and target lesion revascu-
larization (TLR), retrospectively.
Results: We had obtained 1826 lesions follow-up angiography. (83.6%) The mean
clinical follow up period was 78815 days. There were no signiﬁcant differences in
patient background and lesion characteristics except HD. (SF group: 30.4% versus
non-SF group: 4.2%; p< 0.001) However, there was no signiﬁcant difference in the
calciﬁcation lesion between the two group. (N.S.) SF was observed in 26 of 1823
lesions (1.4%). The rate of TLR and late stent thrombosis were signiﬁcantly higher in
the SF group than in the non-SF group (33.3% versus 5.4%; p< 0.001 and 3.7%
versus 0.1%; p¼0.02). MACE was signiﬁcantly higher in the SF group than in the
non-SF group (44.4% versus 10.9%; p< 0.001).
Conclusions: SF after second generation DES implantation occurs in 1.4% of lesions
and is associated with higher rate of TLR, MACE, and late stent thrombosis.
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Background: We aimed to evaluate the incidence and predictors of late catch-up
phenomenon after ﬁrst and second generation drug-eluting stent (DES) implantations.
Methods: From 2002 to 2012, 10996 lesions received DES implantation: ﬁrst gen-
eration, 6242 sirolimus-eluting stents (SES); second generation, 3391 everolimus-
eluting stents (EES) and 1363 biolimus-eluting stents (BES). Mid-term angiographic
follow-up was scheduled at 8 months and late-term at 20 months. We analyzed 6849
lesions (SES, 3871; EES, 2153; and BES, 825) after late-term follow-up, which were
free from in-stent restenosis (ISR) and target lesion revascularization at mid-term
follow-up. ISR was deﬁned as restenosis >50% and late catch-up phenomenon as the
ﬁrst ISR over one year after DES implantation. The follow-up duration was two years.
Results: The late catch-up phenomenon rate was not signiﬁcantly different between
EES and SES (5.8% vs. 7.1%, p¼0.06) but signiﬁcantly lower in BES than in SES
(4.4% vs. 7.1%, p¼0.004). The predictors of late catch-up phenomenon (p< 0.10,
univariate analysis) were hypertension, diabetes, hemodialysis, ostial lesion in the
right coronary artery or in the left circumﬂex artery, ISR lesion, reference diameter
< 2.5 mm, percent diameter stenosis before (>75%) or after (>25%) DES implan-
tation, angulated lesion, lesion length >30 mm, chronic total occlusion lesion, left
main trunk stenting, and DES types, from which 10 variables in the ﬁnal multivariable
regression model obtained by the forward stepwise method are shown in the table.Conclusions: BES implantation is a negative predictor of late catch-up phenomenon.
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non-target lesion (TL) segments and the process of in-stent neoatherosclerosis (NA)
ﬁve years after DES implantation is unknown.
Methods: The SIRTAX-LATE OCT population was analyzed for evidence of in-stent
NA as assessed by OCT ﬁve years after DES (sirolimus-eluting stent (SES) and
paclitaxel-eluting stent (PES)) implantation. NA was deﬁned as the presence of
ﬁbrocalciﬁc plaques or ﬁbroatheromas within the neointima of previously implanted
DES with longitudinal extension of >1.5mm. Native coronary artery disease pro-
gression in non-TL segments was evaluated by serial quantitative coronary angiog-
raphy (QCA) in all arterial segments with diameter of at least 1.5mm and length of at
least 10mm. The minimal lumen diameter (MLD) was serially assessed within
matched segments at baseline and ﬁve year angiographic follow-up, or prior to any
non-TL revascularization. The change in MLD between baseline and follow-up was
calculated as endpoint related to angiographic disease progression. The clinical
endpoint was any non-TL revascularization assessed throughout 5 years by an inde-
pendent clinical event committee.
Results: A total of 88 patients with 88 lesions were available for OCT analysis 5 years
after DES implantation. In-stent neoatherosclerosis was observed in 14% of all stented
segments with the majority of patients having ﬁbroatheromas (12.5%) followed by
ﬁbrocalciﬁc plaques (5.6%). A total of 716 untreated native coronary artery segments
(8.11.7 segments/patient) were serially evaluated by QCA. The change in MLD
between baseline and ﬁve year angiographic follow-up was signiﬁcantly higher in
patients with OCT evidence of NA (0.25mm, 95%CI 0.15-0.35) as compared with
patients without evidence of NA (0.13mm, 95%CI 0.09-0.17, p¼0.002). Consistent
with the angiographic ﬁndings, any revascularization in non-TL segments occurred
more frequently in patients with evidence of NA (79%) as compared with patients
without evidence of NA (47%, p¼0.02).
Conclusions: Patients with angiographic and clinical evidence of native coronary
artery disease progression in non-TL segments are more likely to develop in-stent
neoatherosclerosis.
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Background: Neoatherosclerosis after drug eluting stent (DES) implantation is
known to be related with increased risk of late restenosis and stent thrombosis. Studies
have suggested that inﬂammation by polymer may be one of several mechanisms, but
there have been a few data about bioabsorbable polymer DES (BP-DES) versus du-
rable polymer DES (DP-DES). The aim of study is to compare neoatherosclerosis and
relevant clinical outcomes between BP-DES and DP-DES by Optical Coherence
Tomography (OCT) analysis.
Methods: A total of 292 patients undergoing OCT analysis after DES implantation
were enrolled, who were divided into 2 groups according to stent type [BP-DES
(n¼107) and DP-DES (n¼185)]. OCT analysis was performed within 2 years after
stent implantation. Neoatherosclerosis was deﬁned as presence of more or 1 of as
followings; plaque rupture, thrombus, neovascularization, plaque erosion, micro-
vessel, macrophage and thin of thick ﬁbrous cap atheroma. The primary end point was
the incidence of neoatherosclerosis, and the secondary end point was the occurrence of
MACE (major advanced cardiac events; death, myocardial infarction, target lesion
revascularization, or stent thrombosis).
Results: Demographic, clinical, lesional and procedural characteristics were not
signiﬁcantly different between the two groups. The incidence of neoatherosclerosis
was lower in the BP-DES group than in the DP-DES group (16.8% vs. 30.8%,
p¼0.008). The rate of MACEs did not show signiﬁcant difference between two groups
(9.3% vs. 14.7%, p¼0.208). The Incidence of neoatherosclerosis was not signiﬁcantly
different at 1 year but was lower in BP-DES group than in the DP-DES group between
1 and 2 years (13.9% vs. 29.8%, p¼0.007).
Conclusions: In this 2 year follow-up study, patients undergoing BP-DES implan-
tation had lower rates of neoatherosclerosis than patient with DP-DES, but it did not
translate into better clinical outcomes.
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Background: In-stent neoatherosclerosis has emerged as an important contributing
factor for late stent failure including very late stent thrombosis (VLST) and restenosis.
Clinical imaging modalities, however, have limited capability of evaluating the
presence and characteristics of neoatherosclerosis. The aim of the current pathologic
study was to investigate the prevalence of neoatherosclerosis in lesions with late stentr 13–17, 2014 j TCT Abstracts/Coronary Lesions - In-stent Restenosis
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMfailure following bare metal (BMS) and 1st- and 2nd-generation (gen) drug-eluting
stent (DES) placement.
Methods: All available material from our autopsy stent registry with duration of
implant >30 days to include a total of 384 cases (mean age¼6113 years, 287 male)
with 614 stented lesions in native coronary arteries (BMS¼266 [median, 832 days],
1st-gen DES¼285 [383 days], and 2nd-gen DES¼63 lesions [210 days]) were
pathologically evaluated for the involvement of neoatherosclerosis in stent thrombosis
and restenosis.
Results: The prevalence of VLST (>1 year) was greater in 1st-gen DES (19%) as
compared with BMS (3%) and 2nd-gen DES (0%), where in-stent plaque rupture from
neoatherosclerosis accounted for 83% of VLST in BMS (5 of 6) and 15% of VLST in
1st-gen DES (5 of 33). The involvement of neoatherosclerosis in VLST increased with
time; for duration of implants >3 years, all VLST in BMS (5 of 5) and 33% of VLST
in 1st-gen DES (4 of 12) were attributed to in-stent rupture. VLST from in-stent
rupture occurred earlier in 1st-gen DES (1434579 days) vs. BMS (2376545 days).
Of the 10 lesions with in-stent rupture, only 4 (BMS¼3, 1st-gen DES¼1) had in-stent
restenosis. In BMS, restenosis with underlying neoatherosclerosis was observed only
>3 years, and neoatherosclerosis accounted for 38% of BMS restenosis >3 years. In
contrast, both 1st- and 2nd-gen DES showed restenosis with neoatherosclerosis even
1 year. While only limited cases were available for 2nd-gen DES >1 year, 1st-gen
DES showed increased involvement of neoatherosclerosis in restenosis over time,
accounting for 31% of restenosis between 1 and 3 years and 78% of restenosis
>3 years.
Conclusions: Substantial involvement of neoatherosclerosis in late stent failure is
observed in both BMS and DES, which increases over time.
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Background: Noninferiority of biolimus-eluting stent (BES, Nobori) to everolimus-
eluting stent (EES, Xience) in clinical outcomes of drug-eluting stent (DES) im-
plantation has been reported; however, the difference in long-term clinical and
angiographic outcomes between them in the real world was little known. We aimed to
compare the two-year clinical and angiographic outcomes between EES and BES.
Methods: From 2010 to 2012, 4754 lesions received DES implantation: EES, 3391
lesions and BES, 1363 lesions. Midterm angiographic follow-up was scheduled at 8
months and late-term at 20 months. Target lesion revascularization (TLR) was deﬁned
as clinically or angiographically driven TLR. The TLR rate was calculated by the
Kaplan-Meier methods and compared by the long-rank test. Additionally, we analyzed
2978 lesions (EES, 1153 and BES 825) after late-term follow-up, which were free
from in-stent restenosis (ISR) and TLR at mid-term follow-up. ISR was deﬁned as
restenosis >50% and late catch-up phenomenon as the ﬁrst ISR over one year after
DES implantation.
Results: Between EES and BES, there were no signiﬁcant differences in the rates of
midterm restenosis (7.9% vs. 8.6%, p¼0.51), late catch-up phenomenon (5.8% vs.
4.4%, p¼0.13), and TLR (6.4% vs. 7.0%, log-rank p¼0.47). Meanwhile, in a sub-
group analysis, BES was signiﬁcantly more effective than EES to prevent late catch-
up phenomenon in lesion length 30 mm and ostial lesion in the right coronary artery
(see ﬁgure).Conclusions: The treatment effect on late catch-up phenomenon compared between
BES and EES implantations could depend on speciﬁc lesion characteristics.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoTCT-657
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Background: One of the hypothesized long-term clinical beneﬁts of Absorb BVS
(Abbott Vascular, Santa Clara, CA) is plaque regression and stabilization (reduction in
necrotic and lipid composition). This could also potentially mitigate in-stent
neoatherosclerosis, a late adverse effect that may be responsible for recurrent acute
coronary episodes. We present interim 1-year imaging evaluation (from an ongoing
4-year longitudinal study) of neointimal characteristics after coronary placement of
Absorb BVS in an atherosclerotic familial hypercholesterolemic (FH) swine model.
Methods: After 1 week of hypercholesterolemic diet, coronary arteries were balloon-
injured. After next 20 weeks on diet, injured segments were implanted with BVS (n¼
23) and everolimus-eluting metallic stents (EES, n¼11). Interim angiography, IVUS
and OCT were performed again at 1 year. OCT analysis included previously published
qualitative neointimal tissue assessment according to its pattern of backscatter and
optical intensity (homogeneous, heterogeneous or layered).
Results: At 1-year, all the scaffolds/stents were well apposed, widely patent and fully
covered with neointima. The scaffold thickness remained unchanged from baseline. The
percentage of OCT cross-sections with homogeneous pattern (previously linked to more
ﬁbrotic and less inﬂammatory histopathologic appearance) was signiﬁcantly higher in
BVS than EES (60% vs. 38%, p< 0.05). Also, the incidence of calcium around struts
trended lower for BVS (13.0%vs. 36.4%p¼0.11). Plaque tissue characterization (iMAP-
IVUS, Boston Scientiﬁc) showed lower absolute (0.200.17 mm2) and relative (63%)
lipid component area inBVSvs.EES(0.350.24mm2and83%, respectively, p<0.05).
Conclusions: One year after implantation in the familial hypercholesterolemic (FH)
swine model, the appearance of neointima by endovascular imaging suggests a more
stable and mature composition in BVS than in the EES, yet with less calciﬁcation.
This ongoing study is hoped to provide serial annual insights out to 4 years into the
long-term arterial response to BVS and EES in experimental atherosclerotic setting.
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Background: The mechanism and patterns of in-stent restenosis (ISR) comparing
bare metal stents (BMS) and 1st and 2nd generation drug-eluting stent (DES) as
evaluated by intravascular ultrasound (IVUS) have not been well delineated.
Methods: IVUS evaluation of in-stent restenosis (ISR) included core-lab based
assessments of morphology including ISR pattern (focal [< 10 mm] vs diffuse
[10 mm]), and/or any associated mechanical complication.
Results: There were 298 ISR lesions including 52 BMS, 73 sirolimus-eluting stents
(SES), 52 paclitaxel-eluting stents (PES), 16 zotarolimus-eluting stents (ZES), and
105 everolimus-eluting stent (EES) (Table). Mean pt age was 66.71.1 yrs, 74% were
male, 48.7% had diabetes mellitus, and 48.7% presented with acute coronary syn-
drome. BMS restenosis presented later (5.85.6 yrs) with more intimal hyperplasia.
Although reference lumen areas were similar among BMS and 1st and 2nd generation
DES, restenotic DES were longer and more often underexpanded with associated stent
fracture that was not seen in restenotic BMS.ronary Lesions - In-stent Restenosis B191
